Results overview: Found 15 records in 0.02 seconds.
Articles, 15 records found
Articles 15 records found  1 - 10next  jump to record:
1.
6 p, 1.1 MB Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study / Nahi, Hareth (Karolinska Institute. Department of Medicine) ; Usmani, Saad Z. (Memorial Sloan Kettering Cancer Center) ; Mateos, M. V (Hospital Universitario de Salamanca) ; van de Donk, Niels W C J (Department of Hematology. Vrije Universiteit Amsterdam) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Plesner, Torben (Vejle Hospital and University of Southern Denmark) ; Bandyopadhyay, Nibedita (Janssen Research & Development. LLC) ; Hellemans, Peter (Janssen Research & Development) ; Tromp, Brenda (Janssen Research & Development. LLC) ; Nnane, Ivo (Janssen Research & Development. LLC) ; Zemlickis, Donna (Janssen Research & Development. LLC) ; Chari, Ajai (Icahn School of Medicine at Mount Sinai) ; Moreau, Philippe (University Hospital Hôtel-Dieu (Nantes, França))
2023 - 10.1080/10428194.2022.2148221
Leukemia and Lymphoma, Vol. 64 Núm. 2 (2023) , p. 468-472  
2.
13 p, 471.4 KB Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial / Dimopoulos, Meletios (National and Kapodistrian University of Athens) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nahi, Hareth (Department of Medicine. Karolinska University) ; San-Miguel, J (Clínica Universidad de Navarra) ; Bahlis, Nizar J. (University of Calgary) ; Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ; Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ; Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ; Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ; Plesner, Torben (University of Southern Denmark) ; Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ; Ben Yehuda, Dina (Hematology Department. Hebrew University) ; Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ; Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ; Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ; Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ; Qin, Xiang (Janssen Research & Development (Xina)) ; Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ; Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ; Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ; Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ; Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599  
3.
12 p, 1.6 MB Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma / Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Hebraud, Benjamin (Institut Universitaire du Cancer de Toulouse-Oncopole) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Colin, Anne-Laurène (Ser Centre Hospitalier et Universitaire de Toulouse) ; Ríos Tamayo, Rafael (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ; Hulin, Cyrille (Department of Hematology. Hôpital Haut-Lévêque) ; Blanchard, María Jesús (Hospital Ramón y Cajal) ; Caillot, Denis (Hôpital du Bocage) ; Sureda, Anna (Universitat de Barcelona) ; Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ; Arnulf, Bertrand (Hôpital St-Louis) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Macro, Margaret (Centre Hospitalier et Universitaire de Caen) ; San-Miguel, J (Clínica Universidad de Navarra) ; Belhadj, Karim (Centre Hospitalier et Universitaire Henri Mondor) ; Lahuerta, J. J (Clínica Universidad de Navarra) ; Garelik, M.Brigid (Bristol-Myers Squibb Company) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Moreau, Philippe (University Hospital Hôtel-Dieu, Nantes, France)
Objective: Providing the most efficacious frontline treatment for newly diagnosed multiple myeloma (NDMM) is critical for patient outcomes. No direct comparisons have been made between bortezomib + lenalidomide + dexamethasone (VRD) and bortezomib + thalidomide + dexamethasone (VTD) induction regimens in transplant-eligible NDMM. [...]
2023 - 10.3389/fonc.2023.1197340
Frontiers in Oncology, Vol. 13 (2023) , p. 1197340  
4.
12 p, 583.7 KB Factors associated with critical care requirements in diabetic patients treated with dexamethasone for COVID-19 infection in the first wave of the pandemia / Batule, Sol (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Soldevila i Madorell, Berta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Figueredo, Carme (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Julián, María Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Egea Cortés, Laia (Institut Germans Trias i Pujol. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya) ; Reyes-Urueña, Juliana (Institut Germans Trias i Pujol. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya) ; Casabona-Barbarà, Jordi (Institut Germans Trias i Pujol. Centre d'Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya) ; Mateu, Lourdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Clotet Sala, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; López, Rosa (Institut Català de la Salut) ; Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Diabetes mellitus (DM) and hyperglycemia are important risk factors for poor outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19). The aim of the present study was to analyze the factors associated with the composite outcome of the necessity of invasive mechanical ventilation (IMV) or admission to the intensive care unit (ICU) in subjects with severe COVID-19 infection treated with dexamethasone comparing patients with DM vs. [...]
2022 - 10.3389/fendo.2022.1009028
Frontiers in Endocrinology, Vol. 13 (december 2022)  
5.
11 p, 1.1 MB Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant : a randomized trial / Puig, Noemi (Hospital Universitario de Salamanca) ; Hernández, Miguel Teodoro (Hospital Universitario de Canarias (La Laguna)) ; Rosiñol, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; González, Esther (Hospital Universitario de Cabueñes (Gijón)) ; De Arriba, Felipe (Instituto Murciano de Investigación Biosanitaria) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; González-Calle, Verónica (Hospital Universitario de Salamanca) ; Escalante, Fernando (Hospital Universitario de León) ; de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ; Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ; Ríos-Tamayo, Rafael (Instituto de Investigación Sanitaria de Granada) ; García-Sánchez, Ricarda (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Arguiñano, José M (Complejo Hospitalario de Navarra) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Gutiérrez, Norma C. (Hospital Universitario de Salamanca) ; Calasanz, M.J (Clínica Universidad de Navarra) ; Martín, María L. (Hospital Universitario 12 de Octubre (Madrid)) ; Couto, María del Carmen (Hospital Universitario Virgen de Valme (Sevilla, Andalusia)) ; Casanova, María (Hematology Department. Hospital Costa del Sol de Marbella) ; Arnao, Mario (Hospital Universitari i Politècnic La Fe (València)) ; Pérez-Persona, Ernesto (Instituto de Investigación Sanitaria Bioaraba (Vitoria, País Basc)) ; Garzón, Sebastián (Hospital del SAS de Jerez) ; González, Marta S. (Hospital Universitario de Santiago) ; Martín-Sánchez, Guillermo (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Ocio, Enrique M. (Hospital Universitario de Salamanca) ; Coleman, Morton (Division of Hematology and Oncology. Weill Cornell Medicine) ; Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ; Vale, Ana M. (CHUAC) ; Teruel, Ana I. (Hospital Clínic Universitari (València)) ; Cortés-Rodríguez, María (Hospital Universitario de Salamanca) ; Paiva, Bruno (Clínica Universidad de Navarra) ; Cedena, María Teresa (Hospital Universitario 12 de Octubre (Madrid)) ; San-Miguel, J (Clínica Universidad de Navarra) ; Lahuerta, J. J (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Niesvizky, Ruben (Division of Hematology and Oncology. Weill Cornell Medicine) ; Mateos, M. V (Hospital Universitario de Salamanca)
Although case-control analyses have suggested an additive value with the association of clarithromycin to continuous lenalidomide and dexamethasone (Rd), there are not phase III trials confirming these results. [...]
2021 - 10.1038/s41408-021-00490-8
Blood Cancer Journal, Vol. 11 Núm. 5 (may 2021) , art. 101  
6.
10 p, 306.4 KB Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study / Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ; Leleu, Xavier (CHU de Poitiers) ; Touzeau, Cyrille (Université d'Angers) ; Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Paner, Agne (Rush University Medical Center) ; Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ; Cavo, Michele (Bologna University School of Medicine) ; Maisel, Christopher (Baylor Scott & White Charles A) ; Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ; Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ; Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ; Laubach, Jacob (Harvard Medical School) ; Nadeem, Omar (Harvard Medical School) ; Sandberg, Anna (Oncopeptides AB (Suècia)) ; Orre, Marie (Oncopeptides AB (Suècia)) ; Torrång, Anna (SDS Life Science (Suècia)) ; Bakker, Nicolaas A (Oncopeptides AB) ; Richardson, Paul G.. (Harvard Medical School) ; Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648  
7.
21 p, 4.0 MB Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres / Rodrigo, MJ (Instituto de Salud Carlos III) ; Garcia-Herranz, D (Hospital Clínico San Carlos (Madrid)) ; Aragón-Navas, Alba (Hospital Clínico San Carlos (Madrid)) ; Subias, M (Universidad de Zaragoza. Miguel Servet Ophthalmology Research Group) ; Martínez-Rincón, Teresa (Universidad de Zaragoza. Miguel Servet Ophthalmology Research Group) ; Mendez-Martínez, S (Universidad de Zaragoza. Miguel Servet Ophthalmology Research Group) ; Cardiel, MJ (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; García-Feijoo, J (Universidad Complutense de Madrid. Departamento de Inmunología, Oftalmología y Otorrinolaringología) ; Ruberte, Jesús (Universitat Autònoma de Barcelona. Departament de Sanitat i d'Anatomia Animals) ; Herrero-Vanrell, Rocío (Hospital Clínico San Carlos (Madrid)) ; Pablo, Luis E (Universidad de Zaragoza. Miguel Servet Ophthalmology Research Group) ; Garcia-Martin, Elena (Universidad de Zaragoza. Miguel Servet Ophthalmology Research Group) ; Bravo-Osuna, Irene (Hospital Clínico San Carlos (Madrid))
To evaluate a new chronic glaucoma model produced by intracameral injection of dexamethasone-loaded poly lactic-co-glycolic acid microspheres (Dex-PLGA-Ms) over six months. Healthy rats received two injections (at baseline and Week 4) of Dex-PLGA-Ms into the anterior chamber of the right eye. [...]
2021 - 10.1080/10717544.2021.1998245
Drug Delivery, Vol. 28 (november 2021) , p. 2427-2446  
8.
16 p, 945.2 KB Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH) / Gutierrez, Mª del Mar (Institut d'Investigació Biomèdica Sant Pau) ; Mur, Isabel (Institut d'Investigació Biomèdica Sant Pau) ; Mateo, María Gracia (Institut d'Investigació Biomèdica Sant Pau) ; Vidal, Francesc (Hospital Universitari Joan XXIII de Tarragona. Institut d'Investigació Sanitària Pere Virgili) ; Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau)
Introduction: When coronavirus infectious disease-2019 (COVID-19) blew up, ill-fated auguries on the collision between COVID-19 and the human immunodeficiency virus (HIV) epidemics loomed. Areas covered: Data from observational studies suggest similar incidence attacks of SARS-CoV-2 infection in people living with HIV (PLWH) and HIV-uninfected populations. [...]
2021 - 10.1080/14656566.2021.1887140
Expert Opinion on Pharmacotherapy, Vol. 22 Núm. 9 (2021) , p. 1127-1141  
9.
13 p, 1.0 MB Effect of a recent parenteral dexamethasone and ketoprofen administration on the immunological diagnosis of tuberculosis in goats / Ortega, Javier (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; De Juan Ferré, Lucía (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; Sevilla, Iker A. (Instituto Vasco de Investigación y Desarrollo Agrario. NEIKER-Tecnalia) ; Garrido, Joseba M. (Instituto Vasco de Investigación y Desarrollo Agrario. NEIKER-Tecnalia) ; Roy, Álvaro (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; Velasco, Carlos (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; Romero, Beatriz (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; Domínguez, Mercedes (Centro Nacional de Microbiología (Espanya)) ; Pérez de Val, Bernat (Unitat mixta d'investigació IRTA-UAB en Sanitat Animal. Centre de Recerca en Sanitat Animal) ; Nebot, Carolina (Universidad de Santiago de Compostela. Laboratorio de Higiene, Inspección y Control de Alimentos) ; Sáez-Llorente, José Luis (Ministerio de Agricultura, Pesca y Alimentación) ; Álvarez, Julio (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria) ; Bezos, Javier (Universidad Complutense de Madrid. Centro de Vigilancia Sanitaria Veterinaria)
Caprine tuberculosis (TB) is a zoonosis caused by members of the Mycobacterium tuberculosis complex (MTBC). Caprine TB eradication programmes are based mainly on intradermal tuberculin tests and slaughterhouse surveillance. [...]
2022 - 10.3389/fvets.2022.1042428
Frontiers in Veterinary Science, Vol. 9 (november 2022)  
10.
15 p, 1.2 MB Childhood maltreatment interacts with hypothalamic-pituitary-adrenal axis negative feedback and major depression : effects on cognitive performance / Salvat-Pujol, Neus (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Labad, Javier (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Urretavizcaya, Mikel (Universitat de Barcelona) ; De Arriba-Arnau, Aida (Instituto de Salud Carlos III) ; Segalàs, Cinto (Department of Clinical Sciences) ; Real, Eva (Instituto de Salud Carlos III) ; Ferrer, Alex (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Crespo, José M. (Universitat de Barcelona) ; Jiménez-Murcia, Susana (Instituto de Salud Carlos III) ; Soriano-Mas, Carles (Universitat Autònoma de Barcelona) ; Menchón Magriñá, José Manuel (Universitat de Barcelona) ; Soria, Virginia (Universitat de Barcelona) ; Universitat Autònoma de Barcelona
Background : Childhood maltreatment (CM) is associated with impaired hypothalamic-pituitary-adrenal (HPA) axis negative feedback and cognitive dysfunction, resembling those abnormalities linked to major depressive disorder (MDD). [...]
2021 - 10.1080/20008198.2020.1857955
European Journal of Psychotraumatology, Vol. 12 (march 2021)  

Articles : 15 records found   1 - 10next  jump to record:
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.